A recent subgroup analysis of the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) trial showed that IL-1β-targeting therapy may decrease heart failure-related hospitalization and mortality (38). This evidence concerns the gene IL1B and deep vein thrombosis.